Avacta Group plc develops novel cancer therapies and advanced diagnostic tools, focusing primarily on oncology therapeutics. The company utilizes its proprietary platforms, Affimer® and pre|CISION™, to create targeted peptide and antibody drug conjugates aimed at improving treatment outcomes while minimizing toxicity. Avacta is transitioning to a pure-play oncology company by divesting its diagnostics division, concentrating on the development of its therapeutic candidates, including AVA6000, AVA6103, and AVA7100, which target solid tumors. The company operates primarily in the biotechnology sector, serving patients with cancer and collaborating with partners in the healthcare industry.